Navigation Links
New Afatinib (BIBW 2992) Data in Non-Small Cell Lung Cancer Patients Presented at the 2010 ESMO Congress
Date:10/11/2010

RIDGEFIELD, Conn., Oct. 11 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.  In the phase IIb/III LUX-Lung 1 study, afatinib tripled the secondary endpoint of progression free survival (PFS) but did not extend the primary endpoint of overall survival (OS) in late-stage patients with non-small cell lung cancer (NSCLC).(1)      

Afatinib is an investigational orally administered irreversible inhibitor of both the epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2) tyrosine kinases.  Afatinib is under development in several solid tumors including NSCLC, breast and head and neck cancer.

The LUX-Lung 1 trial compared afatinib to placebo in over 580 patients with advanced NSCLC who had received chemotherapy and a prior EGFR tyrosine kinase inhibitor (EGFR TKI; gefitinib or erlotinib);(1) results show:

  • Afatinib did not improve OS compared to placebo – 10.78 months vs. 11.96 months, respectively (HR = 1.08, 95% CI 0.86 to 1.35)(1)
  • As a secondary endpoint, afatinib extended PFS three-fold compared to placebo (3.3 months vs. 1.1 months) (HR = 0.38, 95% CI 0.31 to 0.48, p<0.0001).  The improvement in PFS was apparent across all patient subgroups and has been confirmed by independent review(1)
  • At 8 weeks, there was a significantly higher disease control rate (stable disease and tumor shrinkage) in those patients who took afatinib (58%) vs. those taking placebo (19%), which was also independently verified (p<0.0001)(1)
  • Improvement of the lung cancer-related symptoms of cough, dyspnea and pain was observed in the afatinib arm vs. placebo.  In addition, the time to deterioration of cough, individual dyspnea items an
    '/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
5. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
8. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... 19, 2014 Aufgrund der ... äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die ... verfügbar unter pharmaserialisation.com , zeigt die Serialisierungsanforderungen ... in Kraft treten. Für international tätige ... um das "ob", sondern darum, "wann" sie die ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. ... Inc. (PGDx), a provider of advanced cancer ... Medicines , a leader in discovering and developing ... today disclosed the first-ever comprehensive genomic study of ... deadly cancer of the female reproductive system, also ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 Ticket ... presale tickets for her 2015 “Honeymoon” Tour. This ... ARIANA-2015 for additional savings at the checkout. , Ariana Grande ... MO (Independence Event Center) , Feb. 28, 2015: Milwaukee, WI ... MN (Xcel Energy Center) , March 03, 2015: Chicago, IL ...
(Date:9/19/2014)... Sept. 19, 2014 York University researchers say ... can help to detect heightened risk for developing ... are any telltale behavioural signs of dementia., Faculty ... Kara Hawkins who led the study asked the ... cognitive-motor tasks, on dual screen laptop computers. The ...
(Date:9/19/2014)... 2014 The Relaxation Drink Production ... 2014. Industry operators were able to mass produce their ... well as establish distribution contracts with nation-wide retailers. The ... to its novelty; energy drinks have only been in ... operators have been able to establish brands and grow ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... – Buoyed by technological advancements, surgical techniques, and ... become the preferred treatment for several chronic diseases ... liver. Advancements in organ and tissue transplantation have ... patients. Organ transplant today represents a ...
(Date:9/19/2014)... grow well in infertile land, and bear many beans ... is because most legumes have a symbiotic relationship with ... air and then supply the host plant with ammonia ... organs called nodules in their roots. However, if too ... the growth of the plants, because the energy cost ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 4Health News:Simple test can help detect Alzheimer's before dementia signs show: York U study 2Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Long-distance communication from leaves to roots 2
... (BUSM) and Boston Medical Center (BMC) found that patients ... of any type did not experience serious harm. However, ... obstetrics/gynecology setting received the most benefit. The findings, which ... , also conclude that disclosures made in an emergency ...
... controversial because of cost, number of false positives, study ... an electrocardiogram in screenings for heart disorders in competitive ... sudden cardiac death and save lives, say Italian researchers. ... dies every three days from an undetected cardiovascular disorder, ...
... commitment to helping its members lead ... ... of,Oregon announces that it has won four bronze (second-place) Telly Awards,for ... Web site for Regence members. The Telly Awards are widely,considered to ...
... risks , , THURSDAY, July 3 (HealthDay News) -- Doing ... health, a new study shows. , Researchers at the ... had bigger spikes in blood pressure than well-rested people ... regard a task as worthwhile and achievable, they increase ...
... Minn., July 3 The Minnesota Nurses,Association (MNA) announced ... U.S. House of Representatives, Congressional District 3., "Ashwin ... and,he will fight for reforms that will produce real ... Committee Chair, Tom Kelly, RN.,"With his unequivocal support of ...
... July 3 The Minnesota Nurses,Association (MNA) announced ... for U.S. House of Representatives, Congressional District 6., ... he shares a guiding principle,important to Minnesota nurses: ... ability to obtain healthcare," said MNA Political Committee,Chair, ...
Cached Medicine News:Health News:Disclosing violence to primary care or obestetrics/gynecology physicians most beneficial 2Health News:Screening Athletes Could Cut Sudden Cardiac Death Risk 2Health News:Regence Wins Four International Telly Awards for Health and Wellness Videos 2Health News:Working Hard When Tired Raises Blood Pressure 2Health News:Minnesota Nurses Association Endorses Ashwin Madia for Congress 2Health News:Minnesota Nurses Association Endorses Elwyn Tinklenberg for Congress 2
Produce clean 0.75 mm round hole without tissue tags. Serrated squeeze action handle....
Target illumination for day and night testing. Glare luminance distance. The Optec 3500 remote control offers flexible positioning during test administration. Each vision tester includes 12 tests sli...
... The CSV- lOOOHGT instrument provides standardized glare testing. ... Vectorvision test faces for the evaluation of glare ... is precisely calibrated to simulate two on-coming halogen ... feet. The glare level can be adjusted to ...
Ruler S/Steel....
Medicine Products: